

## Product datasheet for **KN403388**

### **NAT13 (NAA50) Human Gene Knockout Kit (CRISPR)**

#### **Product data:**

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	NAT13
Locus ID:	80218



[View online »](#)

**Components:**
**KN403388G1**, NAT13 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

**KN403388G2**, NAT13 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

**KN403388D**, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCCGAG AAGTTGGGG GAGGGGTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGTAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCG CTTTTCCCG AGGGTGGGG AGAACCGTAT
ATAAGTCAG TAGTCGCCG GAACGTTCT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCT GCCTCTTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG
GCTGCAGTAC GTGATTCTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTTCGCCTG TGCTTGAGT GAGGCCTGGC CTGGGCGCTG GGGCCCGCG GTGCGAATCT
GGTGGCACCT TCGCGCCTG CTCGCTGCTT TCGATAAGTC TCTAGCCATT TAAAATTTT GATGACCTGC
TGCAGCGCT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
TTTGGGGCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCGCCCT GGGCGGCAAG GCTGGCCCG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGTTCCCG GCCCTGTGC AGGGAGCTCA AAATGGAGGA CGCGGCGCTC GGGAGAGCGG GCGGGTGAGT
CACCCACACA AAGGAAAAGG GCCTTTCCG CCTCAGCCG CGCTTCATGT GACTCCACGG AGTACCGGGC
GCCCTCCAG CACCTCGATT AGTTCTGAG CTTTTGAGT ACGTGCTCT TAGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGAGACTG AAGTTAGGCC AGCTTGGCAG TTGATGTAAT
TCTCCTTGA ATTTGCCCT TTTGAGTTG GATCTTGGT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCGAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
CGTGATGGC TACGGCTTCT ACCACTTCG CACCTACCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT
TCAGTACCG CTACGAGGCC GGCCGCGTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGCGGAT
AACGATCTGG ATGGCAGCTT CACCCGACC TTCAGCCTGC GCGACGGCGG CTACTIONAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCA TGTTCCCTT
CCGCCCGTG GAGGAGGATC ACAGCAACAC CGAGTGGGG ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGC CACGGTGC GCCTGCCACC GCGACGACGT
CCCCAGGGC GTACGCACC TCGCCGCCG GTTCGCCGAC TACCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGCG CGTCGGGCTC GACATCGGCA
AGGTGTGGT CCGGACGAC GGCGCCCGG TGGCGGTCTG GACCACGCCG GAGAGCGTGC AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGCCG TGGCCCGCA GCAACAGATG
GAAGCCCTC TGCGCCGCA CCGGCCAAG GAGCCCGCT GGTTCCTGGC CACCCTCGGC GTCTCGCCG
ACCACCAGG CAAGGTCTG GGCAGCCCG TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTT CTGGAGACT CCGCGCCCG CAACCTCCC TTCTACGAGC GGCTCGGCT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGCA GCCCGGTGCC TGAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTTTTTTC
ACTGCATTCT AGTTGTGGT TGTCAAAC CATCAATGA TCTTAATAAC TTCGTATAAT GTATGTATA CGAAGTTAT
    
```



**Disclaimer:** These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

**RefSeq:** [NM\\_001308445](#), [NM\\_025146](#)

**UniProt ID:** [Q9GZZ1](#)

**Synonyms:** hNAT5; hSAN; MAK3; NAT5; NAT5P; NAT13; NAT13P; SAN

**Summary:** N-alpha-acetyltransferase that acetylates the N-terminus of proteins that retain their initiating methionine (PubMed:19744929, PubMed:22311970, PubMed:21900231, PubMed:27484799). Has a broad substrate specificity: able to acetylate the initiator methionine of most peptides, except for those with a proline in second position (PubMed:27484799). Also displays N-epsilon-acetyltransferase activity by mediating acetylation of the side chain of specific lysines on proteins (PubMed:19744929). Autoacetylates in vivo (PubMed:19744929). The relevance of N-epsilon-acetyltransferase activity is however unclear: able to acetylate H4 in vitro, but this result has not been confirmed in vivo (PubMed:19744929). Component of a N-alpha-acetyltransferase complex containing NAA10 and NAA15, but NAA50 does not influence the acetyltransferase activity of NAA10: this multiprotein complex probably constitutes the major contributor for N-terminal acetylation at the ribosome exit tunnel, with NAA10 acetylating all amino termini that are devoid of methionine and NAA50 acetylating other peptides (PubMed:16507339, PubMed:27484799). Required for sister chromatid cohesion during mitosis by promoting binding of CDCA5/sororin to cohesin: may act by counteracting the function of NAA10 (PubMed:17502424, PubMed:27422821).[UniProtKB/Swiss-Prot Function]

### Product images:

